IP Library Granted Patent US 9,540,636
Granted Patent B2
US 9,540,636 · App. 15/173,880 · Granted Jan 10, 2017

Method and materials for isolation of nucleic acid materials

Inventors: Sundaresh Brahmasandra (Ann Arbor, MI); Michelle Mastronardi (Ann Arbor, MI); Elizabeth Craig (Ann Arbor, MI); Maureen Carey (Ann Arbor, MI)
Assignee: NeuMoDx Molecular, Inc.
C12N15/1013B01L3/502715B01L3/502746B01L3/502753B01L3/502761C12N15/1006C12Q1/6806B01L2200/0631B01L2300/0627B01L2400/086
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,636
App. No.
15/173,880
Granted
Jan 10, 2017
Kind
B2
Abstract

A method for nucleic acid isolation comprising: receiving a binding moiety solution within a process chamber; mixing the binding moiety solution with a biological sample, within the process chamber, in order to produce a moiety-sample mixture; incubating the moiety-sample mixture during a time window, thereby producing a solution comprising a set of moiety-bound nucleic acid particles and a waste volume; separating the set of moiety-bound nucleic acid particles from the waste volume; washing the set of moiety-bound nucleic acid particles; and releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles. The method preferably utilizes a binding moiety comprising at least one of poly(allylamine) and polypropylenimine tetramine dendrimer, both of which reversibly bind and unbind to nucleic acids based upon environmental pH.

Claims (40)

1. A method for nucleic acid isolation comprising:

receiving a binding moiety solution within a process chamber, wherein the binding moiety solution comprises a collection buffer and a set of affinity moiety-coated microparticles;

contacting the binding moiety solution with a biological sample, within the process chamber, thereby producing a moiety-sample mixture;

incubating the moiety-sample mixture to reversibly bind nucleic acid material of the biological sample to the set of affinity moiety-coated microparticles, thereby producing a set of moiety-bound nucleic acid particles;

receiving a cartridge at a cartridge receiving module comprising a set of pins, each pin in the set of pins displaceable between a first position and a second position;

occluding a fluidic pathway of the cartridge upon displacement of a first subset of the set of pins;

separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture, within the fluidic pathway of the cartridge; and

washing the set of moiety-bound nucleic acid particles within the fluidic pathway of the cartridge, in coordination with displacement of a second subset of the set of pins, wherein displacement of the second subset of pins includes reversal of displacement of at least one pin in the first subset of the set of pins, in reversing occlusion of a portion of the fluidic pathway.

2. The method of claim 1 , wherein the set of affinity moiety-coated microparticles comprises a set of magnetic microparticles, and wherein receiving the binding moiety solution, comprising the set of affinity moiety-coated microparticles, within the process chamber comprises receiving the set of magnetic microparticles, each magnetic microparticle modified with an amine-reactive ester functional group configured to react with one of a set of amine groups of a molecule of Polypropylenimine tetramine dendrimer Generation 1.

3. The method of claim 1 , wherein the set of affinity moiety-coated microparticles comprises a set of magnetic microparticles, wherein receiving the binding moiety solution, comprising the set of affinity moiety-coated microparticles, comprises receiving the set of magnetic microparticles covalently bonded to a set of affinity moiety molecules, and wherein contacting the binding moiety solution with the biological sample comprises aspirating the binding moiety solution along with the biological sample from the process chamber and dispensing the binding moiety solution with the biological sample to the process chamber.

4. The method of claim 3 , wherein separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture comprises magnetically separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture.

5. The method of claim 4 , wherein magnetically separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture comprises aspirating the moiety-sample mixture from the process chamber; occluding the fluidic pathway of the cartridge at a set of occlusion positions upon displacement of pins of the set of pins to generate a path through a magnetic field, and to a waste chamber; and delivering the moiety-sample mixture through the path of the fluidic pathway, such that the set of moiety-bound nucleic acid particles is captured within the magnetic field and a waste volume of the moiety-sample mixture is delivered into the waste chamber.

6. The method of claim 3 , wherein incubating the moiety-sample mixture comprises heating the moiety-sample solution to a temperature above 25° C. for at least 5 minutes, thus simultaneously lysing the biological sample and facilitating binding of nucleic acid material of the biological sample to the set of affinity moiety-coated microparticles.

7. The method of claim 3 , wherein washing the set of moiety-bound nucleic acid particles comprises aspirating the moiety-sample mixture; receiving the cartridge at the cartridge receiving module comprising the set of pins and a cam card interfacing with the set of pins; transitioning the cartridge to an active configuration that disposes the cartridge to a position that is proximal to the set of pins; displacing the first subset of the set of pins in the active configuration of the cartridge, upon translation of the cam card relative to the set of pins, thereby occluding the fluidic pathway of the cartridge at a set of occlusion positions; delivering the moiety-sample mixture into the fluidic pathway, wherein the fluidic pathway is configured to pass through a magnetic field and is coupled to a waste chamber, such that the set of moiety-bound nucleic acid particles is captured within the magnetic field; and delivering a wash solution through the fluidic pathway and into the waste chamber in a continuous flow operation.

8. The method of claim 1 wherein receiving the binding moiety solution comprises receiving a binding buffer configured to aid in mitigation of nucleolytic activity from the biological sample.

9. The method of claim 1 , wherein separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture comprises at least one of filtering the moiety-sample mixture and focusing the moiety-sample mixture.

10. The method of claim 3 , further comprising releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles, wherein releasing the nucleic acid sample comprises: occluding the fluidic pathway of the cartridge, comprising the process chamber, at a set of occlusion positions, upon displacement of pins of the set of pins, to define a path through a magnetic field; delivering the set of moiety-bound nucleic acid particles into the path of the fluidic pathway; and delivering an elution solution into the fluidic pathway, thereby inducing a pH shift configured to release the nucleic acid sample from the set of moiety-bound nucleic acid particles.

11. The method of claim 10 , further comprising capturing the set of moiety-bound nucleic acid particles within the magnetic field and aspirating the nucleic acid sample from the fluidic pathway.

12. The method of claim 1 , further comprising releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles, wherein releasing the nucleic acid sample comprises contacting the set of moiety-bound nucleic acid particles with an elution solution characterized by a pH that is greater than pH 10.

13. The method of claim 1 , further comprising processing a nucleic acid sample, wherein processing the nucleic acid sample comprises modulating the fluidic pathway of the cartridge upon displacement of a third subset of the set of pins, thereby defining a path to a diagnostic chamber of the cartridge, delivering the nucleic acid sample to the diagnostic chamber, and amplifying nucleic acids of the nucleic acid sample within the diagnostic chamber by polymerase chain reaction.

14. A method for nucleic acid extraction, the method comprising:

receiving a binding moiety solution within a process chamber, wherein the binding moiety solution comprises a collection buffer and a set of affinity moiety-coated microparticles;

mixing the binding moiety solution with a biological sample, within the process chamber, thereby producing a moiety-sample mixture;

incubating the moiety-sample mixture to reversibly bind nucleic acid material, comprising target DNA and target RNA, of the biological sample to the set of affinity moiety-coated microparticles, thereby producing a set of moiety-bound nucleic acid particles;

receiving a cartridge at a cartridge receiving module comprising a set of pins, each pin in the set of pins displaceable between a first position and a second position;

occluding a fluidic pathway of the cartridge upon displacement of a first subset of the set of pins; and

magnetically separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture, within the fluidic pathway of the cartridge.

15. The method of claim 14 , further including: eluting a nucleic acid sample comprising target DNA and target RNA from the set of moiety-bound nucleic acid particles, in coordination with displacement of a second subset of the set of pins to modulate flow in the fluidic pathway, thereby facilitating total nucleic acid extraction.

16. The method of claim 15 , wherein magnetically separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture comprises: aspirating the moiety-sample mixture from the process chamber; occluding the fluidic pathway of the cartridge at a set of occlusion positions upon displacement of the first subset of the set of pins to generate a path through a magnetic field, and to a waste chamber of the cartridge; and delivering the moiety-sample mixture through the path of the fluidic pathway, such that the set of moiety-bound nucleic acid particles is captured within the magnetic field and a waste volume of the moiety-sample mixture is delivered into the waste chamber.

17. A method for nucleic acid isolation from a biological sample, comprising:

receiving a binding moiety solution within a process chamber, wherein the binding moiety solution includes a set of affinity moiety-coated microparticles;

producing a moiety-sample mixture upon combination of the binding moiety solution with the biological sample;

producing a set of moiety-bound nucleic acid particles upon incubation of the moiety-sample mixture to reversibly bind nucleic acid material of the biological sample to the set of affinity moiety-coated microparticles;

occluding a fluidic pathway of a cartridge upon displacement of a first subset of a set of pins at the cartridge comprising the set of pins;

separating the set of moiety-bound nucleic acid particles from the moiety-sample mixture, within the fluidic pathway of the cartridge;

washing the set of moiety-bound nucleic acid particles, within the fluidic pathway of the cartridge; and

releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles with an elution solution.

18. The method of claim 17 , wherein occluding the fluidic pathway comprises linearly displacing a cam card comprising a set of hills and valleys, relative to the set of pins, wherein displacing the cam card transitions at least one pin of the set of pins between a first position and a second position.

19. The method of claim 17 , wherein the set of affinity moiety-coated microparticles comprises a set of microparticles amide-bonded to at least one of Poly(allylamine) of molecular weight<40,000 Da and Polypropylenimine tetramine dendrimer Generation 1, and wherein the set of moiety-bound nucleic acid particles comprises the nucleic acid material reversibly bound to the at least one of the Poly(allylamine) of molecular weight<40,000 Da and the Polypropylenimine tetramine dendrimer Generation 1.

20. The of claim 17 , wherein releasing the nucleic acid sample comprises releasing the nucleic acid sample in coordination with displacement of a second subset of the set of pins to modulate flow in the fluidic pathway.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Sep 17, 2020
From: VENTURE LENDING & LEASING VIII, INC.; VENTURE LENDING & LEASING IX, INC.
To: NEUMODX MOLECULAR, INC.
Reel/Frame 053808/0600 →
SECURITY INTEREST Recorded Sep 14, 2018
From: NEUMODX MOLECULAR, INC.
To: VENTURE LENDING & LEASING IX, INC.; VENTURE LENDING & LEASING VIII, INC.
Reel/Frame 047091/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: BRAHMASANDRA, SUNDARESH; MASTRONARDI, MICHELLE; CRAIG, ELIZABETH; CAREY, MAUREEN
To: NEUMODX MOLECULAR, INC.
Reel/Frame 039263/0753 →
Continuity (4)
Continuation 14168760 · Jan 30, 2014
Continuation 14060214 · Oct 22, 2013
Provisional Application 61718634 · Oct 25, 2012
Related Publication 20160281080A1 · Sep 29, 2016